Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Measles Vaccine Outbreaks topic
No spam. Unsubscribe anytime.
Middletown medical director briefs board on measles risks, vaccine schedule amid recent U.S. outbreaks
Summary
Dr. Genowy told the Middletown Board of Health and Environment that measles is highly contagious, has no antiviral treatment, and that vaccination remains the primary prevention; he reviewed U.S. case counts, outbreak concentrations, and the local public-health implications.
MIDDLETOWN, Ohio — At its March 11 meeting, the Middletown Board of Health and Environment heard an educational presentation on measles from the board’s medical director, Dr. Genowy, who reviewed the virus’s symptoms, the U.S. case trend and the current vaccine schedule.
Dr. Genowy told the board, “There is no antiviral treatment, so there's no real medication that can treat it once you contract the virus. But there's an extremely effective vaccine that's been around for quite a while.” He described measles as highly contagious—“9 of 10 close contacts are gonna get it”—and noted that the characteristic rash is “kind of the hallmark symptom.”
The presentation explained why vaccination matters locally. Dr. Genowy said most infections worldwide occur where vaccination coverage is low and that U.S. outbreaks in recent years have been concentrated in small, under‑vaccinated communities. He said 2025 had seen about 220 reported cases through March 7, and that Texas and New Mexico accounted for the bulk of related cases; two deaths had been reported in the current outbreak and, per the doctor, both were children who were not vaccinated.
Dr. Genowy reviewed clinical features and complications: common symptoms include runny nose, cough, fever and conjunctivitis; while most infections are self‑limited, secondary bacterial pneumonia, ear infections and, rarely, encephalitis can occur. “It is very rare. But 1 in a hundred thousand cases” can develop encephalitis, he told the board.
He also summarized the routine U.S. immunization schedule: a first dose at about 12–15 months and a second dose at about 4–6 years, noting that the two‑dose series produces a 95–98 percent immune response after the second dose. Dr. Genowy said national two‑dose coverage remains around the mid‑90s percentage and that herd immunity for measles is commonly estimated at roughly 92 percent.
Board members asked questions about hospitalization thresholds for fever and the rarity of severe complications; Dr. Genowy advised that very high fevers (in children, about 104–105°F) typically prompt hospital evaluation and reiterated that most care is supportive—fluids, antipyretics and treatment of any secondary bacterial infections.
The board did not report any local measles cases at the meeting. Staff said they are monitoring national updates and webinars and are prepared to carry out contact tracing if a local case is identified.
The presentation concluded with a reminder of routine school immunization requirements and available medical exemptions; board members discussed outreach and whether local clinicians and parents are receiving clear information about the recommended two‑dose schedule.
